Bryn Pharma, LLC, a privately held pharmaceutical company on a mission to provide patients and caregivers a better way to treat anaphylaxis, is proud to announce the addition of three new executives and the appointment of Michael Kaseta to its Board of Directors. Nurry Hong has been appointed Chief Strategy and Business Development Officer, Steve Killmeyer is now the Chief Financial Officer, and Lisa Lucifero is the new VP, Head of Human Resources.
These new appointments come at an exciting time as Bryn prepares for the U.S. Food and Drug Administration approval and market launch of its innovative intranasal spray UTULY™, which is being studied for the treatment of type 1 allergic reactions, including anaphylaxis.
Bryn is proud to announce the addition of Nurry, Steve, Lisa, and Mike to its Board of Directors. With a combined wealth of experience and knowledge in the pharmaceutical industry and food allergy space, they will be integral to Bryn achieving its goal of delivering a needle-free epinephrine alternative to the food allergy community.
Sandy Loreaux, Bryn’s CEO, expressed her enthusiasm for the new additions, stating, “These industry veterans bring essential experience and skill sets to Bryn as we continue to advance toward market entry of UTULY. Mike’s financial acumen is a major boost to our Board, and we are excited to have such a remarkable group of leaders to help us provide a truly better way of treating anaphylaxis.”
Nurry Hong is a highly accomplished life sciences executive and biotech entrepreneur with over 20 years of experience in senior management, advisory roles, and venture capital. Currently, he serves as Chief Strategy and Business Development Officer for Bryn, where he works with the leadership team and Board of Directors to create a clear organizational vision and ensure execution of key initiatives.
As a father of a son with multiple food allergies, he is a passionate patient advocate and has dedicated his career to advancing innovations to help those suffering from severe allergies. Over the years, he has helped global public biopharma, private biotech, seed-stage ventures, venture capital and non-profit research organizations.
Most recently, he was the CEO of Pareto Bio, a seed-stage biopharma company advancing innovative microbiome discoveries to treat and prevent atopic diseases including food allergy. He also served as Chief of Strategy and Innovation for Food Allergy Research & Education (FARE). Nurry earned his BA in Business Finance and Information Systems from the University of Washington.
Steve Killmeyer serves as Bryn’s CFO and is responsible for all financial direction and oversight. With over 15 years of experience in the pharmaceutical, biotech, and medical device industries, Steve brings a wealth of knowledge to Bryn. Most recently, he held the role of Head of Finance and Strategy for Aimmune Therapeutics, a Nestle Health Science startup.
Prior to this, Steve was a Life Science M&A consultant at Deloitte Consulting, a healthcare private equity investor at HealthCor Partners, and a healthcare investment banker at Merrill Lynch. He holds an MBA from the Wharton School at the University of Pennsylvania, and a BS in Finance from Carnegie Mellon University.
Lisa Lucifero is Bryn’s VP and Head of Human Resources, where she is responsible for crafting a sound HR strategy to bring in and cultivate top talent as Bryn continues its expansion ahead of the launch of UTULY.
With a wealth of expertise in the pharmaceutical industry, Lisa has a particular focus on organizational design, change leadership, communication and talent acquisition. She has a strong track record of creating programs and practices that foster a positive company culture and drive business results in high-growth organizations.
Before joining Bryn, Lisa held managerial positions at DBV Technologies, Mallinckrodt Pharmaceuticals, Catalent Pharma Solutions, and Sanofi. She earned her Bachelor of Arts in English and Government from Lehigh University and has been certified as a Senior Human Resources Professional (SPHR) since 2008.
Michael Kaseta, a board member of Bryn, is a highly experienced financial executive and board director. He currently serves as the CFO of Liquidia Corporation and previously held the same role at Aerami Therapeutics, Inc., a privately held biotech dedicated to developing improved therapies for severe respiratory diseases.
Prior to joining Aralez, Michael had several roles at global biopharmaceutical company Sanofi S.A. He also serves on the Board of Directors of Alimera Sciences, Inc. and holds a BBA in accounting from James Madison University, with a license as a CPA (inactive) in the state of New Jersey.
About Bryn Pharma
Bryn Pharma is on a mission to revolutionize the epinephrine autoinjector market and provide a better way for people at risk of anaphylaxis to be prepared for a life-threatening allergic reaction.
Founded in 2017 by patients for patients, Bryn Pharma is a privately held pharmaceutical company that strives to make their product accessible and easy to use. With its innovative approach to a necessary medical device, Bryn Pharma is working to positively disrupt the existing market and create a better way to be prepared.